Cheng Jeffrey B, Levine Michael A, Bell Norman H, Mangelsdorf David J, Russell David W
Department of Molecular Genetics, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA.
Proc Natl Acad Sci U S A. 2004 May 18;101(20):7711-5. doi: 10.1073/pnas.0402490101. Epub 2004 May 5.
The synthesis of bioactive vitamin D requires hydroxylation at the 1 alpha and 25 positions by cytochrome P450 enzymes in the kidney and liver, respectively. The mitochondrial enzyme CYP27B1 catalyzes 1 alpha-hydroxylation in the kidney but the identity of the hepatic 25-hydroxylase has remained unclear for >30 years. We previously identified the microsomal CYP2R1 protein as a potential candidate for the liver vitamin D 25-hydroxylase based on the enzyme's biochemical properties, conservation, and expression pattern. Here, we report a molecular analysis of a patient with low circulating levels of 25-hydroxyvitamin D and classic symptoms of vitamin D deficiency. This individual was found to be homozygous for a transition mutation in exon 2 of the CYP2R1 gene on chromosome 11p15.2. The inherited mutation caused the substitution of a proline for an evolutionarily conserved leucine at amino acid 99 in the CYP2R1 protein and eliminated vitamin D 25-hydroxylase enzyme activity. These data identify CYP2R1 as a biologically relevant vitamin D 25-hydroxylase and reveal the molecular basis of a human genetic disease, selective 25-hydroxyvitamin D deficiency.
生物活性维生素D的合成需要分别由肾脏和肝脏中的细胞色素P450酶在1α和25位进行羟基化。线粒体酶CYP27B1催化肾脏中的1α-羟基化,但肝脏25-羟化酶的身份在30多年来一直不清楚。我们之前基于该酶的生化特性、保守性和表达模式,将微粒体CYP2R1蛋白鉴定为肝脏维生素D 25-羟化酶的潜在候选者。在此,我们报告了一名循环中25-羟基维生素D水平低且有维生素D缺乏典型症状患者的分子分析。发现该个体在11号染色体p15.2上的CYP2R1基因外显子2中的一个转换突变是纯合的。遗传突变导致CYP2R1蛋白中第99位氨基酸处一个进化保守的亮氨酸被脯氨酸取代,并消除了维生素D 25-羟化酶的活性。这些数据确定CYP2R1为生物学上相关的维生素D 25-羟化酶,并揭示了一种人类遗传疾病——选择性25-羟基维生素D缺乏症的分子基础。